Vaxcyte(NASDAQ) PCVX

Vaxcyte, Inc. creates vaccines to stop dangerous bacterial infections in adults and children. It focuses on preventing serious conditions like pneumonia and meningitis. The company uses technology to build vaccines that offer broader protection than current options.

Winning the War Against Bacteria

• VAX-31: Investigational vaccine targeting 31 bacterial strains to prevent pneumonia; currently in Phase 3 clinical trials for adults.
• VAX-24: Candidate covering 24 bacterial types; showed positive results in Phase 2 trials for healthy infants.
• VAX-A1: Prophylactic vaccine for Group A Streptococcus; began Phase 1 safety testing in June 2026.
• VAX-XL: Next-generation candidate designed to offer the broadest protection against invasive pneumococcal disease.

Strategic Partners and New Trials

• Secured exclusive manufacturing rights from Sutro Biopharma in Nov. 2023 for a $75 million exercise price.
• Partnered with Lonza in Oct. 2023 to build a specialized manufacturing suite in Visp, Switzerland.
• Established a 15-year supply deal with Thermo Fisher Scientific in Sept. 2025 for drug packaging and testing.
• Completed enrollment for three Phase 3 clinical trials of VAX-31 in adults by May 2026.

Re-Engineering How Vaccines Are Made

Vaxcyte uses its XpressCF cell-free platform to produce complex proteins and antigens. This system bypasses traditional cell-based methods to improve vaccine quality and speed.

Tracking the Clinical Costs

• Research and development costs reached $580.6 million for the six months ended June 30, 2026, up 69.6% year over year.
• Net loss totaled $604.9 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and investments stood at $2.5 billion as of June 30, 2026.
• Net proceeds from an underwritten public offering in Feb. 2026 provided $601.8 million in capital.
• Accumulated deficit for the company was $2.8 billion as of June 30, 2026.

Evolution From Lab to Clinic

Vaxcyte is evolving into a late-stage developer of complex vaccines for global bacterial markets. The company relies on large-scale partnerships to prepare for potential product launches.